Patent Grant
7005439
The present invention relates to novel compounds, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
Chemokines play an important role in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved four cysteine motif. The chemokine superfamily pan be divided into two main groups exhibiting characteristic structural motifs, the Cys-X-Cys (C-X-C) and Cys-Cys (C-C) families. These are distinguished on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues and sequence similarity.
The C-X-C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP-2).
The C-C chemokines include potent chemoattractants of monocytes and lymphocytes but not neutrophils such as human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins 1α and 1β (MIP-1α and MIP-1β).
Studies have demonstrated that the actions of the chemokines are mediated by subfamilies of G protein-coupled receptors, among which are the receptors designated CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR3 and CXCR4. These receptors represent good targets for drug development since agents which modulate these receptors would be useful in the treatment of disorders and diseases such as those mentioned above.
In accordance with the present invention, there is therefore provided a compound of general formula
wherein:
X represents an oxygen atom or a CH2, OCH2, CH2O, CH2NH, NH, carbonyl or sulphonyl group and Y represents a nitrogen atom or a CH or C(OH) group, provided that when X represents an oxygen atom or a CH2O, CH2NH or NH group, then Y represents a CH group;
In the context of the present specification, an alkyl or alkenyl substituent group or an alkyl or alkenyl moiety in a substituent group may be linear or branched. In the definition of R15, it should be noted that the unsaturated 5- to 10-membered heterocyclic ring system may be aliphatic or aromatic.
The integer m is preferably 1 or 2.
Each R1 independently represents halogen (e.g. chlorine, fluorine, bromine or iodine), cyano, nitro, carboxyl, hydroxyl, C3-C6 cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), C1-C6, preferably C1-C4, alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy), C1-C6, preferably C1-C4, alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl), C1-C6, preferably C1-C4, haloalkyl (e.g. trifluoromethyl), C1-C6, preferably C1-C4, haloalkoxy (e.g. trifluoromethoxy), —NR9R10, C3-C6 cycloalkylamino (e.g. cyclopropylamino, cyclobutylamino, cyclopentylamino or cyclohexylamino), C1-C6, preferably C1-C4, alkylthio (e.g. methylthio or ethylthio), C1-C6, preferably C1-C4, alkylcarbonyl (e.g. methylcarbonyl, ethylcarbonyl, n-propylcarbonyl, isopropylcarbonyl, n-butylcarbonyl, n-pentylcarbonyl or n-hexylcarbonyl), C1-C6, preferably C1-C4, alkylcarbonylamino (e.g. methylcarbonylamino or ethylcarbonylamino), sulphonamido, C1-C6, preferably C1-C4, alkylsulphonyl (e.g. methylsulphonyl, ethylsulphonyl, n-propylsulphonyl, isopropylsulphonyl, n-butylsulphonyl, n-pentylsulphonyl or n-hexylsulphonyl), —C(O)NR11R12, —NR13C(O)—(NH)pR14, phenyl, or C1-C6, preferably C1-C4, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by carboxyl or C1-C6, preferably C1-C4, alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl).
Most preferably, each R1 independently represents halogen (particularly chlorine or fluorine), cyano, nitro, C1-C6 alkoxy (especially methoxy), C1-C6 alkylcarbonyl (especially methylcarbonyl) or C1-C6 alkylcarbonylamino (particularly methylcarbonylamino). Each R1 especially represents halogen or cyano.
Preferably X represents an oxygen atom or a CH2 or NH group.
Preferred combinations of Y, Z1 and Z2 include:
Q preferably represents an oxygen atom.
Each R3 independently represents a C1-C6, preferably C1-C4, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), C1-C6, preferably C1-C4, alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl), —CH2OH or carboxyl group. It is preferred that R3 represents a methyl, methoxycarbonyl, ethoxycarbonyl, —CH2OH or carboxyl group.
R4, R5, R6 and R7 each independently represent a hydrogen atom or a C1-C6, preferably C1-C4, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), or R4, R5, R6 and R7 together represent a C1-C4 alkylene chain linking the two carbon atoms to which they are attached to form a 4- to 7-membered saturated carbocycle (e.g. cyclohexyl or preferably cyclopentyl), or R5, R6 and R7 each represent a hydrogen atom and R4 and R8 together with the carbon atoms to which they are attached form a 5- to 6-membered saturated carbocycle (preferably cyclopentyl).
R8 represents a hydrogen atom, a C1-C6, preferably C1-C4, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) or is linked to R4 as defined above.
R9 and R10 each independently represent a hydrogen atom or a C1-C6, preferably C1-C4, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), or R9 and R10 together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocycle.
R1l and R12 each independently represent a hydrogen atom or a C1-C6, preferably C1-C4, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by a C1-C6, preferably C1-C4, alkoxycarbonyl substituent group.
R13 represents a hydrogen atom or a C1-C6, preferably C1-C4, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl).
R14 represents a hydrogen atom, or a C1-C6, preferably C1-C4, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by carboxyl, C1-C6, preferably C1-C4, alkoxy or C1-C6, preferably C1-C4, alkoxycarbonyl.
R15 represents a group C2-C6, preferably C2-C4, alkyl group (e.g. ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl or n-pentyl), C2-C6, preferably C2-C4, alkenyl, C3-C6 cycloalkyl (e.g. cyclobutyl or cyclopentyl), C5-C6 cycloalkenyl, adamantyl, phenyl or a saturated or unsaturated 5- to 10-membered heterocyclic ring system comprising at least one heteroatom selected from nitrogen, oxygen and sulphur, wherein each group may be optionally substituted by one or more (e.g. one, two, three or four) substituents independently selected from nitro, hydroxyl, oxo, halogen (e.g.; fluorine, chlorine, bromine or iodine), carboxyl, C1-C6, preferably C1-C4, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), C1-C6, preferably C1-C4, alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy), C1-C6, preferably C1-C4, alkylthio (e.g. methylthio or ethylthio), C1-C6, preferably C1-C4, alkylcarbonyl (e.g. methylcarbonyl, ethylcarbonyl, n-propylcarbonyl, isopropylcarbonyl, n-butylcarbonyl, n-pentylcarbonyl or n-hexylcarbonyl), C1-C6, preferably C1-C4, alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl), phenyl and —NHC(O)—R17.
The saturated or unsaturated 5- to 10-membered heterocyclic ring system may be monocyclic or polycyclic (e.g. bicyclic) and may comprise up to four heteroatoms independently selected from nitrogen, oxygen and sulphur. Examples of ring systems that may be used include pyrrolidinyl, piperidinyl, pyrazolyl, thiazolidinyl, thienyl, isoxazolyl, thiadiazolyl, pyrrolyl, furanyl, thiazolyl, indolyl, quinolinyl, benzimidazolyl, triazolyl, tetrazolyl and pyridinyl.
Each R16 independently represents halogen (e.g. chlorine, fluorine, bromine or iodine), cyano, nitro, carboxyl, hydroxyl, C3-C6 cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), C1-C6, preferably C1-C4, alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy), C1-C6, preferably C1-C4, alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl), C1-C6, preferably C1-C4, haloalkyl (e.g. trifluoromethyl), C1-C6, preferably C1-C4, haloalkoxy (e.g. trifluoromethoxy), —NR18 R19 C3-C6 cycloalkylamino (e.g. cyclopropylamino, cyclobutylamino, cyclopentylamino or cyclohexylamino), C1-C6, preferably C1-C4, alkylthio (e.g. methylthio or ethylthio), C1-C6, preferably C1-C4, alkylcarbonyl (e.g. methylcarbonyl, ethylcarbonyl, n-propylcarbonyl, isopropylcarbonyl, n-butylcarbonyl, n-pentylcarbonyl or n-hexylcarbonyl), C1-C6, preferably C1-C4, alkylcarbonylamino (e.g. methylcarbonylamino or ethylcarbonylamino), sulphonamido, C1-C6, preferably C1-C4, alkylsulphonyl (e.g. methylsulphonyl, ethylsulphonyl, n-propylsulphonyl, isopropylsulphonyl, n-butylsulphonyl, n-pentylsulphonyl or n-hexylsulphonyl), —C(O)NR21R22, —NR23C(O)—(NH)vR24, phenyl, or C1-C6, preferably C1-C4, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, is tert-butyl, n-pentyl or n-hexyl) optionally substituted by carboxyl or C1-C6, preferably C1-C4, alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl).
Preferably, each R16 independently represents halogen (particularly chlorine or fluorine), cyano, C1-C4 alkoxy (especially methoxy), C1-C4 alkoxycarbonyl (especially methoxycarbonyl), C1-C4 haloalkyl (especially trifluoromethyl), C1-C4 alkylcarbonyl (particularly methylcarbonyl), phenyl or C1-C4 alkyl (e.g. methyl or tert-butyl). Each R16 is especially a halogen atom or methyl group.
R17 represents a C1-C6, preferably C1 -C4, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), amino or phenyl group.
R18 and R19 each independently represent a hydrogen atom or a C1-C6, preferably C1-C4, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), or R19 and R20 together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocycle.
R20 and R21 each independently represent a hydrogen atom or a C1-C6, preferably C1-C4, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by a C1-C6, preferably C1-C4, alkoxycarbonyl substituent group.
R22 represents a hydrogen atom or a C1-C6, preferably C1-C4, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl).
R23 represents a hydrogen atom, or a C1-C6, preferably C1-C4, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by carboxyl, C1-C6, preferably C1-C4, alkoxy or C1-C6, preferably C1-C4, alkoxycarbonyl.
Preferred compounds of the invention include:
The present invention further provides a process for the preparation of a compound of formula (I) as defined above which comprises reacting a compound of general formula
or a salt thereof (e.g. an acid addition salt such as a hydrochloride salt), wherein m, n, t, R1, R3, R4, R5, R6, R7, R8, R16, Q, Z1 and Z2 are as defined in formula (I), with a compound of general formula
R15—CO2H (III)
or chemically equivalent derivative thereof (e.g. acyl halide or anhydride derivative) wherein R15 is as defined in formula (I);
The process of the invention may conveniently be carried out in a solvent, e.g. an organic solvent such as an alcohol (e.g. methanol or ethanol), a hydrocarbon (e.g. toluene), an amine (e.g. triethylamine or diisopropylethylamine) or acetonitrile at a temperature of, for example, 15° C. or above, such as a temperature in the range from 20 to 120° C.
Compounds of formulae (II) and (III) are either commercially available, are well known in the literature or may be prepared easily using known techniques.
It will be appreciated by those skilled in the art that in the process of the present invention certain functional groups such as hydroxyl or amino groups in the starting reagents or intermediate compounds may need to be protected by protecting groups. Thus, the preparation of the compounds of formula (I) may involve, at an appropriate stage, the removal of one or more protecting groups.
The protection and deprotection of functional groups is described in ‘Protective Groups in Organic Chemistry’, edited by J. W. F. McOmie, Plenum Press (1973) and ‘Protective Groups in Organic Synthesis’, 2nd edition, T. W. Greene and P. G. M. Wuts, Wiley-Interscience (1991).
The compounds of formula (I) above may be converted to a pharmaceutically acceptable salt or solvate thereof, preferably an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate or p-toluenesulphonate.
Compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses the use of all geometric and optical isomers of the compounds of formula (I) and mixtures thereof including racemates. The use of tautomers and mixtures thereof also form an aspect of the present invention.
The compounds of formula (I) have activity as pharmaceuticals, in particular as modulators of chemokine receptor (especially MIP-1α chemokine receptor) activity, and may be used in the treatment of autoinmnune, inflammatory, proliferative and hyperproliferative diseases and immunologically-mediated diseases including rejection of transplanted organs or tissues and Acquired Immunodeficiency Syndrome (AIDS).
Examples of these conditions are:
Thus, the present invention provides a compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.
In a further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.
In the context of the present specification, the term “therapy” also includes “prophylaxis” unless there are specific indications to the contrary. The terms “therapeutic” and “therapeutically” should be construed accordingly.
The invention also provides a method of treating an inflammatory disease in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.
The invention still farther provides a method of treating an airways disease in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.
For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated. The daily dosage of the compound of formula (I) may be in the range from 0.001 mg/kg to 30 mg/kg.
The compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt/solvate (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99% w (per cent by weight), more preferably from 0.05 to 80% w, still more preferably from 0.10 to 70% w, and even more preferably from 0.10 to 50% w, of active ingredient, all percentages by weight being based on total composition.
The present invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
The invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, with a pharmaceutically acceptable adjuvant, diluent or carrier.
The pharmaceutical compositions may be administered topically (e.g. to the lung and/or airways or to the skin) in the form of solutions, suspensions, heptafluoroalkane aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions, or by subcutaneous administration or by rectal administration in the form of suppositories or transdermally.
The invention will now be further explained by reference to the following illustrative examples, in which 1H NMR spectra were recorded on Varian Unity Inova 400. The central solvent peak of chloroform-d (δH 7.27 ppm) were used as internal standard. Low resolution mass spectra and accurate mass determination were recorded on a Hewlett-Packard 100 LC-MS system equipped with APCI/ESI ionisation chambers. All solvents and commercial reagents were laboratory grade and used as received. The nomenclature used for the compounds was generated with ACD/IUPAC Name Pro. The following abbreviations are used in the examples:
N-(5-Chloro-{2-3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-isobutyramide
a) N-(5-Chloro-2-hydroxy-pheny)-isobutyramide
In a flask was added 4-chloro-2-aminophenol (1.2 g, 8.39 mmole) and water (25 ml). The suspension was vigorously stirred and isobutyric anhydride (1.6 ml, 10.5 mmole) was added. The mixture was heated to 60° C. for 30 minutes under vigorous stirring. The emulsion was cooled, and a precipitate was formed, which was collected through filtration. The solid was washed twice with water on the filter and was finally dried to give 1.4 g (78%) of the sub-title compound as a white solid.
1H-NMR(400 MHz, DMSO-d6)δ: 10.11 (1H, s); 9.12 (1H, s); 7.94 (1H, d, J2.5 Hz); 6.95 (1H, dd, J 8.7 2.6 Hz); 6.84 (1H, d, J 8.5 Hz); 2.79 (1H, p, J 6.7 Hz); 1.08 (6H, d, J 6.8 Hz)
b) N-(5-Chloro-2-oxiranylmethoxy-phenyl)-isobutyramide
In a vial was added the compound obtained in a) (0.4 g, 1.87 mmole), epibromohydrin (0.28 g, 2.06 mmole), K2CO3 (0.5 g, 3.7 mmole) and DMF (2 ml). The vial was sealed and heated with stirring (2 hours, 60° C.). The mixture was then partitioned between EtOAc and water, and the organic phase was washed twice with water and once with brine, and was finally evaporated to give a brown solid. The crude epoxide was purified on silica, to give 0.22 g (44%) of the sub-title compound as a white solid.
c) In a vial was added the compound obtained in b) (0.026 g, 0.13 mmole), 3-(4-chlorophenoxy)-pyrrolidine (0.035 g, 0.13 mmole) in ethanol (2 ml). The vial was sealed and heated with stirring at 75° C. for 3 hours. The solution was allowed to cool, and the solvent was evaporated. The crude product was purified on silica, and the pure fractions were collected. The title compound was lyophilized as the hydrochloride, giving 0.055 g (84%) as a white solid. The compound was a mixture of four stereoisomers, which had an effect on the NMR-spectra.
1H-NMR (400 MHz, DMSO-d6)δ: 10.84-10.34 (1H, m); 9.12 (1H, s); 8.09 (1H, s); 7.36 (2H, dd, J 9.2 1.3 Hz); 7.11-7.00 (3H, m); 7.00 (2H, d, J 8.8 Hz); 6.22-6.06 (1H, m); 5.22-5.10 (1H, m); 4.34 (1H, bs); 4.08-3.96 (1.5H, m); 3.95-3.87 (1H, m); 3.83-3.66 (1.5H, m); 3.61-3.23 (3H, m); 2.86 (1H, sept, J 6.6 Hz); 2.64-2.51 (½H, m); 2.36-2.14 (1H, m); 2.14-2.00 (½H, m); 1.08 (6H, d, J 6.7 Hz)
APCI-MS: m/z 467.2 [MH+]
Aniline Intermediate 1
1-(2-aminophenoxy)-3-[4-(3,4-dichlorophenoxy)-1-piperidinyl]-2-propanol dihydrochloride
N-(2-{3-[4-(3,4-dichlorophenoxy)-1-piperidinyl]-2-hydroxypropoxy}phenyl)acetamide (1.418 g, 3.13 mmol, prepared by analogy to Example 1) was dissolved in 50 ml HCl (35%/aq, puriss) and refluxed overnight. The product precipitated and was filtered and dried to give 0.835 g (65%) of the title compound.
APCI-MS m/z: 411, 413 [MH+]
1H NMR (400 MHz, CDCl3): δ 8.39-3.31 (m, 2H), 7.3 1 (d, 1H), 7.01-6.98(m, 3H), 6.94-6.91(m, 1H), 6.75(dd, 1H), 4.31(m, 1H), 4.12-4.02 (m, 2H), 3.92(dd, 1H), 2.90(m, 1H), 2.69(m, 1H), 2.62-2.51(m, 2H), 2.46(dd, 1H), 2.34(m, 1H), 2.18(s, 3H), 2.04-1.93(m, 2H), 1.89-1.77(m, 2H).
Aniline Intermediate 2
1-[(2-aminophenyl)oxyl]-3-{3-[(4-chlorophenyl)oxyl-]1-pyrrolidinyl}-2-propanol dihydrochloride
Prepared according to the method described in Aniline Intermediate 1.
APCI-MS m/z: 363, 365 [MH+]
The intermediate anilines 1 and 2 described above were used in the following examples.
Thiophene-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide
To a solution of 80 uL 0.2M 2-thiophenecarboxylic acid in NMP were HBTU (80 uL, 0.2M/NMP), HoBT (80 uL, 0.2M/NMP), DIEA (30 uL, 0.5M/NMP) and pyridine (30 uL, 0.5M/NMP) added and stirred for 30 minutes before 1-[(2-aminophenyl)oxy]-3-{3-[(4-chlorophenyl)oxy]-1-pyrrolidinyl}-2-propanol (75 uL, 0.2M/NMP) was added. The mixture was stirred overnight at room temperature before it was concentrated under reduced pressure to dryness. The product was diluted with 1000 uL dichloromethane and washed with with sat.NaHCO3/aq (800 uL), 1.81% HCl/aq(800 uL) and sat. NaCl/aq. The organic layer was concentrated under reduced pressure to dryness and used without further purification. Yield 3.6mg, 51%
APCI-MS m/z: 473.2 [MH+]
1H NMR (400 MHz, CD3OD): δ 8 7.88-7.85 (d, 1H), 7.74-7.65 (m, 2H), 7.34-7.28 (m, 2H), 7.27-7.21(m, 1H), 7.20-7.15 (m, 1H), 7.14-7.09 (dd, 1H), 7.06-7.00 (m, 1H), 6.96-6.91 (m, 2H), 5.18-5.12 (m, 1H), 4.39-4.30 (m, 1H), 4.19-3.24 (m, 9H), 2.66-2.11 (m, 3H)
The following Examples 3 to 53 were prepared by methods analogous to the method described in Example 2.
N-[(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenylcarbamoyl)-methyl]-benzamide
APCI-MS m/z: 524.3 [MH+]
Pyrazine-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide
APCI-MS m/z: 469.2 [MH+]
Cyclohexanecarboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide
APCI-MS m/z: 473.3 [MH+]
N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-phthalamic acid methyl ester
APCI-MS m/z: 525.2 [MH+]
N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-3-hydroxy-butyramide
APCI-MS m/z: 449.2 [MH+]
N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl-2-ureido-acetamide
APCI-MS m/z: 463.2 [MH+]
4-Acetylamino-N-(2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-butyramide
APCI-MS m/z: 490.3 [MH+]
1-Acetyl-piperidine-4-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide
APCI-MS m/z: 516.3 [MH+]
N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-3-methoxy-benzamide
APCI-MS m/z: 497.2 [MH+]
2-Acetylamino-N-(2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-3-methyl-butyramide
APCI-MS m/z: 504.3 [MH+]
2-Acetylamino-N-(2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-3-hydroxy-butyramide
APCI-MS m/z: 506.2 [MH+]
Adamantane-1-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide
APCI-MS m/z: 525.3 [MH+]
2-Acetylamino-N-(2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-3-phenyl-propionamide
APCI-MS m/z: 552.3 [MH+]
N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-2-methoxy-benzamide
APCI-MS rn/z: 497.2 [MH+]
5-Methyl-thiophene-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide
APCI-MS m/z: 487.2 [MH+]
1-Acetyl-pyrrolidine-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide
APCI-MS m/z: 502.3 [MH+]
1,5-Dimethyl-1H-pyrazole-3-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide
APCI-MS m/z: 485.3 [MH+]
5-Oxo-pyrrolidine-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide
APCI-MS m/z: 474.2 [MH+]
1H-Indole-6-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl1-2-hydroxy-propoxy}-phenyl)-amide
APCI-MS m/z: 506.2 [MH+]
Cyclobutanecarboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide
APCI-MS m/z: 445.3 [MH+]
N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl) propionamide
APCI-MS m/z: 419.2 [MH+]
Pentanoic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide
APCI-MS m/z: 447.3 [MH+]
Pent-4-enoic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide
APCI-MS m/z: 445.3 [MH+]
Cyclopentanecarboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide
APCI-MS m/z: 459.3 [MH+]
Cyclopropanecarboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide
APCI-MS m/z: 431.2 [MH+]
N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-isobutyramide APCI-MS m/z: 433.3 [MH+]
N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-2-methylsulfanyl-acetamide
APCI-MS m/z: 451.2 [MH+]
2-Acetylamino-N-(2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-propionamide
APCI-MS m/z: 476.2 [MH+]
N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-butyramide
APCI-MS m/z: 433.3 [MH+]
N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-3-methyl-butyramide
APCI-MS m/z: 447.3 [MH+]
N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-2-methoxy-acetamide
APCI-MS m/z: 435.2 [MR+]
N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxyl-phenyl})-2,2-dimethyl-propionamide
APCI-MS m/z: 447.2 [MH+]
5-Oxo-hexanoic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide
APCI-MS m/z: 475.3 [MH+]
Hexanoic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide
APCI-MS m/z: 461.3 [MH+]
2-Chloro-N-(2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-benzamide
APCI-MS m/z: 501.2, 503.2 [MH+]
3-Chloro-N-(2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-benzamide
APCI-MS m/z: 501.2, 503.2 [MH+]
(4R)-N-(2-{3-[3-(4-chlorophenoxy)-1-pyrrolidinyl]-2-hydroxypropoxy}phenyl)-1.3-thiazolidine-4-carboxamide ditrifluoroacetate
APCI-MS m/z: 478.2 [MH+]
Thiophene-2-carboxylic acid (2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide
APCI-MS m/z: 521.0, 523.0 [MH+]
N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-benzamide
APCI-MS m/z: 515.2, 517.2[MH+]
N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-nicotinamide
APCI-MS m/z: 516.2, 518.2 [MH+]
Pyridine-2-carboxylic acid (2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide
APCI-MS m/z: 516.2, 518.2 [MH+]
N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-isonicotinamide
APCI-MS m/z: 516.2, 518.2 [MH+]
Cyclohexanecarboxylic acid (2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide
APCI-MS m/z: 521.3, 523.3 [MH+]
N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-3-hydroxy-butyramide
APCI-MS m/z: 497.2, 499.3 [MH+]
5-Methyl-thiophene-2-carboxylic acid (2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide
APCI-MS m/z: 535.2, 537.2 [MH+]
Cyclobutanecarboxylic acid (2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide
APCI-MS m/z:493.3, 495.2 [MH+]
N-(2-(3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxyl-phenyl)-propionamide
APCI-MS m/z: 467.2, 469.2 [MH+]
Pentanoic acid (2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide
APCI-MS m/z: 495.3, 497.3 [MH+]
Pent-4-enoic acid (2-{3-14-(3,4-dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide
APCI-MS m/z: 493.3 ,495.2 [MH+]
Cyclopentanecarboxylic acid (2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide
APCI-MS m/z: 507.3, 509.3 [MH+]
N-(2-13-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxyl-phenyl)-3-methyl-butyramide
APCI-MS m/z: 495.3,497.3 [MH+]
N-(2-{3-[3-(4-chlorophenoxy)-1-pyrrolidinyl]-2-hydroxypropoxy}phenyl)-2,2,2-trifluoroacetamide hydrochloride
A mixture of 1-(2-aminophenoxy)-3-[3-(4-chlorophenoxy)-1-pyrrolidinyl]-2-propanol (10 mg, 0.022 mmol), dichloromethane (3 ml) and Triethyl amine was cooled in an ice bath. A solution of Trifluoro acetic anhydride (3.51 μl, 0.025 mmol) in dichloromethane (2 ml) was then added and the mixture stirred at 0° C. until reaction completion. The mixture was diluted with dichloromethane, washed with 1M H2SO4, water, dried over natrium sulphate and concentrated to give an oil. The oil was treated with 1.0M ethereal HCl solution to give the product as solid (9 mg).
APCI-MS: m/z 459, 460 [MH+]
4-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenylcarbamoyl)-3-methyl-butyric acid
1-(2-aminophenoxy)-3-[4-(3,4-dichlorophenoxy)-1-piperidinyl]-2-propanol (75 uL, 0.2M/NMP) was mixed with 3-methyl glutaric anhydride (3 eq, 225 uL 0.2M /NMP) to get a product containing both esther and amide. After evaporation of the mixture it was treated with 3 eq 0.5M LiOH in (THF/water 1:4) for two hours at 80° C. to hydrolyse the esther. The reaction mixture was diluted with more water (2 mL) and the desired product was extracted with 5×500 uL EtOAc which was evaporated to dryness.
APCI-MS m/z: 539.2, 541.2 [MH+]
N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-succinamic acid
Prepared according to the method described in Example 55.
APCI-MS m/z: 511.2, 513.2 [MH+]
Aniline Intermediate 3
1-(2-amino-5-methylphenoxy)-3-[3-(4-chlorophenoxy)-1-pyrrolidinyl]-2-propanol
APCI-MS m/z: 377.2, 379.1 [MH+]
1H NMR (400MHz, CDCl3): δ 7.26-7.21 (m, 2H), 6.79-6.74 (m, 211), 6.67-6.62 (m, 3H), 4.83-4.76 (m, 1H), 4.15-4.06 (m, 1H), 4.04-4.00 (d, 2H), 3.73-3.64 (s, 2H), 3.47-3.35 (s, 1H), 3.14 -2.56 (m, 6H), 2.36-2.22(m, 4H), 2.05-1.95(m, 1H)
Aniline Intermediate 4
1-(2-amino-5-methylphenoxy)-3-[3-(4-fluorophenoxy)-1-pyrrolidinyl]-2-propanol
APCI-MS mz: 361.1 [MH+]
1H NMR (400MHz, CDCl3): δ 7.00-6.94 (m, 2H), 6.81-6.76 (m, 2H), 6.67-6.62 (m, 3H), 4.81-4.74 (m, 1I1), 4.15-4.06 (m, 1H), 4.03-3.99 (m, 2H), 3.88-3.36 (m, 3H), 3.12-2.56 (m, 6H), 2.33-2.23(m, 4H), 2.05-1.96(m, 1H)
The compounds of Examples 57 to 85 were prepared using one of the Aniline Intermediates 3 and 4.
Furan-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}4-methyl-phenyl)-amide
APCI-MS m/z: 471.5, 473.5 [MH+]
1H-Pyrrole-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide
APCI-MS m/z: 470.5, 472.5 [MH+]
Thiophene-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide
APCI-MS m/z: 487.5, 489.5 [MH+]
Cyclopentanecarboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide
APCI-MS m/z: 473.6, 475.5 [MH+]
5-Methyl-thiophene-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide
APCI-MS m/z: 501.5, 503.5 [MH+]
3-Chloro-thiophene-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide
APCI-MS m/z: 521.5, 532.5 [MH+]
5-Methyl-isoxazole-4-carboxylic acid (2-{3-[13-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide
APCI-MS m/z: 486.5, 488.6 [MH+]
[1,2,3]Thiadiazole4-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide
APCI-MS m/z: 489.5, 491.5[MH+]
3-Methyl-furan-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide
APCI-MS m/z: 485.5, 487.6 [MH+]
Cyclopent-1-enecarboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide
APCI-MS m/z: 471.6, 473.6 [MH+]
2-Methyl-furan-3-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide
APCI-MS m/z: 485.6, 487.6 [MH+]
3-Methyl-thiophene-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide
APCI-MS m/z: 501.6, 503.5 [MH+]
5-Nitro-1H-pyrazole-3-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide
APCI-MS m/z: 516.5, 518.5 [MH+]
Thiophene-3-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide
APCI-MS m/z: 487.5, 489.5 [MH+]
Cyclobutanecarboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide
APCI-MS m/z: 459.5,461.5 [MH+]
Furan-2-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide
APCI-MS m/z: 455.5 [MH+]
1H-Pyrrole-2-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide
APCI-MS m/z: 454.6 [MH+]
Thiophene-2-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide
APCI-MS m/z: 471.5 [MH+]
3-Chloro-thiophene-2-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide
APCI-MS m/z: 505.5, 507.5 [MH+]
5-Methyl-isoxazole-4-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide
APCI-MS m/z: 470.5 [MH+]
3-Methyl-furan-2-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide
APCI-MS m/z: 469.6 [MH+]
Cyclopent-1-enecarboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide
APCI-MS m/z: 455.6 [MH+]
2-Methyl-furan-3-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide
APCI-MS m/z: 469.6 [MH+]
3-Methyl-thiophene-2-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide
APCI-MS m/z: 485.5 [MH+]
5-Chloro-thiophene-2-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide
APCI-MS m/z: 505.5, 507.5 [MH+]
Thiophene-3-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}4-methyl-phenyl)-amide
APCI-MS m/z: 471.5 [MH+]
2,5-Dimethyl-furan-3-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide
APCI-MS m/z: 483.6 [MH+]
Cyclobutanecarboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide
APCI-MS m/z: 443.6 [MH+]
Furan-3-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide
APCI-MS m/z: 455.5 [MH+]
N-{2-[(3-{3-[(4-fluorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxypropyl)oxy]-4-methylphenyl}-1H-pyrrole-2-carboxamide
APCI-MS: m/z 454.1 [MH+]
N-{2-[(3-{3-[(4-chlorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxypropyl)oxy]-4-methylphenyl}-3-thiophenecarboxamide
APCI-MS: m/z 471.1 [MH+]
N-{2-[(3-{3-[(4-chlorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxy-2-methylpropyl)oxy]phenyl}-2-thiophenecarboxamide, compound with trifluoroacetic acid
Aniline intermediate 3 (60 mg, 0.159 mmol), 2-thiophenecarboxylic acid (20.4 mg, 0.159 mmol) and HATU (72 mg, 0.191 mmol) were stirred in dichloromethane (2 ml).
Diisopropylethylamine was added to pH 8. The mixture was stirred overnight and then concentrated. The residue was purified on silica (dichloromethane/methanol 98/2) followed by purification on C18 (2 g Isolute, acetonitrile/water 20/80 to 35/65 with 0.5% trifluoroacetic acid) to give the title compound (75 mg, 79%).
1H-NMR (400MHz, MeOD): δ 7.86 (m, 1H), 7.72 (m, 1H), 7.50 (m, 1H), 7.29 (m, 3H), 7.16 (m, 2H), 7.07 (m, 1H), 6.91 (m, 2H), 5.10 (m, 1H), 3.82-4.17 (m, 4H), 3.24-3.69 (m, 4H), 2.13-2.64 (m, 2H), 1.38 (m, 3H).
MS-APCI+: m/z 487 [MH+]
N-{2-[(3-{3-[(4-fluorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxypropyl)oxy]-4-methylphenyl}-2-thiophenecarboxamide
APCI MS APCI-MS: m/z 471.1 [MH+]
N-{2-[(3-{3-[(4-chlorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxypropyl)oxy]phenyl}-2-furancarboxamide
APCI-MS: m/z 456.9 [MH+]
N-{2-[(3-{3-[(4-chlorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxypropyl)oxylphenyl}-1-pyrrole-2-carboxamide
APCI-MS: m/z 456.1 [MH+]
N-{2-[(3-{3-[(4-chlorophenyl)oxy]-1-pyrrolidinyl}-2hydroxypropyl)oxy]4-methylphenyl}-1H-pyrrole-3-carboxamide
APCI-MS: m/z 470.0 [MH+]
N-{2-[(3-{3-[(4-fluorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxypropyl)oxy]-4-methylphenyl}-2-furancarboxamide
APCI-MS: m/z 455.1 [MH+]
N-{2-[(3-{3-[(4-chlorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxy-2-methylpropyl)oxy]phenyl}cyclopentanecarboxamide, compound with trifluoracetic acid
The compound (80 mg, 86%) was prepared from aniline intermediate 3 (60 mg, 0.159 mmol) and cyclopentanecarboxylic acid (18 μl, 0.159 mmol) as described in Example 88.
1H-NMR (400MHz, MeOD): δ 7.59 (m, 1H), 7.29 (m, 2H), 7.19 (m, 1H), 7.09 (m, 1H), 6.97 (m, 3H), 5.17 (m, 1H), 3.86-4.23 (m, 4H), 3.35-3.73 (m, 4H), 2.86 (m, 1H), 1.45 (bs, 3H).
MS-APCI+: m/z 473 [MH+]
N-(2-{3-[3-(4-Fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-2-methyl-propoxy}-phenyl)-benzamide
The compound was prepared using an analogous method as in Example 88.
APCI-MS: m/z 465 [MH+]
N-(2-{3-[3-(4-Cyano-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-2-methyl-propoxy}-phenyl)-benzamide
The compound was prepared using an analogous method as in Example 88.
APCI-MS: m/z 472 [MH+]
N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-2-methyl-propoxy}-phenyl)-benzamide
The compound was prepared using an analogous method as in Example 88.
APCI-MS: m/z 529 [MH+]
N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-2-methyl-propoxy}-phenyl)-benzamide
The compound was prepared using an analogous method as in Example 88.
APCI-MS: m/z 481 [MH+]
N-(2-{3-[4-(3,4-Dichloro-phenylamino)-piperidin-1-yl]-2-hydroxy-2-methyl-propoxy}-phenyl)-benzamide
The compound was prepared using an analogous method as in Example 88.
APCI-MS: m/z 528 [MH+]
THP-1 Chemotaxis Assay
Introduction
The assay measured the chemotactic response elicited by MIP-1α chemokine in the human monocytic cell line THP-1. The compounds of the Examples were evaluated by their ability to depress the chemotactic response to a standard concentration of MIP-1 α chemokine.
Methods
Culture of THP-1 cells
Cells were thawed rapidly at 37° C. from frozen aliquots and resuspended in a 25 cm flask containing 5 ml of RPMI-1640 medium supplemented with Glutamax and 10% heat inactivated fetal calf serum without antibiotics (RPMI+10% HIFCS). At day 3 the medium is discarded and replaced with fresh medium.
THP-1 cells are routinely cultured in RPMI-1640 medium supplemented with 10% heat inactivated fetal calf serum and glutamax but without antibiotics. Optimal growth of the cells requires that they are passaged every 3 days and that the minimum subculture density is 4×10+5 cells/ml.
Chemotaxis assay
Cells were removed from the flask and washed by centrifugation in RPMI+10% HIFCS+glutamax. The cells were then resuspended at 2×10+7 cells/ml in fresh medium (RPMI+10% HIFCS+glutamax) to which was added calcein-AM (5 gl of stock solution to 1 ml to give a final concentration of 5×10−6M). After gentle mixing the cells were incubated at 37° C. in a CO2 incubator for 30 minutes. The cells were then diluted to 50 ml with medium and washed twice by centrifugation at 400×g. Labelled cells were then resuspended at a cell concentration of 1×10+7 cells/ml and incubated with an equal volume of MIP-1α antagonist (10−10M to 10−6M final concentration) for 30 minutes at 37° C. in a humidified CO2 incubator.
Chemotaxis was performed using Neuroprobe 96-well chemotaxis plates employing 8 μm filters (cat no. 101-8). Thirty microlitres of chemoattractant supplemented with various concentrations of antagonists or vehicle were added to the lower wells of the plate in triplicate. The filter was then carefully positioned on top and then 25 μl of cells preincubated with the corresponding concentration of antagonist or vehicle were added to the surface of the filter. The plate was then incubated for 2 hours at 37° C. in a humidified CO2 incubator. The cells remaining on the surface were then removed by adsorption and the whole plate was centrifuged at 2000 rpm for 10 minutes. The filter was then removed and the cells that had migrated to the lower wells were quantified by the fluorescence of cell associated calcein-AM. Cell migration was then expressed in fluorescence units after subtraction of the reagent blank and values were standardized to % migration by comparing the fluorescence values with that of a known number of labelled cells. The effect of antagonists was calculated as % inhibition when the number of migrated cells were compared with vehicle.
| Number | Date | Country | Kind |
|---|---|---|---|
| 0002330 | Jun 2000 | SE | national |
| 0003980 | Oct 2000 | SE | national |
The present application is a national phase application under 35 U.S.C. Section 371 filed from International Patent Application PCT/SE01/01378, filed 14 Jun. 2001, which claims priority to Swedish patent application Ser. No. 0002330-9, filed 20 Jun. 2000 and Swedish patent application Ser. No. 0003980-0, filed 31 Oct. 2000. The contents of these applications are incorporated herein by reference in their entirety.
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/SE01/01378 | 6/14/2001 | WO | 00 | 12/17/2002 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO01/98272 | 12/27/2001 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 3203992 | Kunz et al. | Aug 1965 | A |
| 3577432 | Helsley | May 1971 | A |
| 3755584 | Plotnikoff et al. | Aug 1973 | A |
| 3818017 | Janssen et al. | Jun 1974 | A |
| 3894030 | Janssen et al. | Jul 1975 | A |
| 4029801 | Cavalla et al. | Jun 1977 | A |
| 4166119 | Effland et al. | Aug 1979 | A |
| 4264613 | Regnier et al. | Apr 1981 | A |
| 4338323 | Regnier et al. | Jul 1982 | A |
| 5576321 | Krushinski, Jr. et al. | Nov 1996 | A |
| 5614523 | Audia et al. | Mar 1997 | A |
| 5614533 | Anderson et al. | Mar 1997 | A |
| 5627196 | Audia et al. | May 1997 | A |
| 5741789 | Hibschman et al. | Apr 1998 | A |
| 5789402 | Audia et al. | Aug 1998 | A |
| Number | Date | Country |
|---|---|---|
| 37 23 568 | Jan 1989 | DE |
| 37 23 648 | Jan 1989 | DE |
| 197 03 131 | Jul 1998 | DE |
| 197 55 268 | Jun 1999 | DE |
| 0 095 454 | Nov 1983 | EP |
| 0 128 007 | Dec 1984 | EP |
| 0 496 691 | Jul 1992 | EP |
| 0 587 311 | Mar 1994 | EP |
| 0 722 941 | Jul 1996 | EP |
| 0 903 349 | Mar 1999 | EP |
| 2.190.430 | Jun 1972 | FR |
| 1368012 | Sep 1974 | GB |
| WO 9325528 | Dec 1993 | WO |
| WO 9723458 | Jul 1997 | WO |
| WO 9832442 | Jul 1998 | WO |
| WO 9925686 | May 1999 | WO |
| WO 9931092 | Jun 1999 | WO |
| WO 9965895 | Dec 1999 | WO |
| WO 0035449 | Jun 2000 | WO |
| WO 0053600 | Sep 2000 | WO |
| WO 0058305 | Oct 2000 | WO |
| WO 0069820 | Nov 2000 | WO |
| WO 0114333 | Mar 2001 | WO |
| WO 0143744 | Jun 2001 | WO |
| WO 0144227 | Jun 2001 | WO |
| WO 0187839 | Nov 2001 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20030153555 A1 | Aug 2003 | US |
